Document:

THIS WARRANT AND ANY SECURITIES ACQUIRED
UPON THE EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES
LAWS AND MAY NOT BE TRANSFERRED, SOLD OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT WITH RESPECT
TO THE SECURITIES EVIDENCED BY THIS CERTIFICATE, FILED AND MADE EFFECTIVE UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND SUCH
APPLICABLE STATE SECURITIES LAWS, OR UNLESS SOLD PURSUANT TO AN EXEMPTION FROM SUCH REGISTRATION REQUIREMENTS PROVIDED THAT THE
COMPANY RECEIVES AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY TO THE EFFECT THAT REGISTRATION UNDER SUCH ACT AND SUCH APPLICABLE
STATE SECURITIES LAWS IS NOT REQUIRED.

 

	Warrant Certificate No. 2014-10	Dated: April 15, 2014

 

WARRANT

 

ENUMERAL BIOMEDICAL CORP.

 

Expiring: April 15, 2019

 

THIS IS TO CERTIFY THAT, for value received,
Arthur Tinkelenberg (the “Holder”), is entitled, subject to certain conditions set forth in Sections 1.01 and 1.02
hereof, to purchase from Enumeral Biomedical Corp., a Delaware corporation (the “Company”), at the Company’s
principal executive office, at a price per share of $2.125 (the “Exercise Price”), up to 58,823 shares (the “Warrant
Shares”) of the Company’s Series B Preferred Stock, $0.0001 par value per share (“Series B Preferred Stock”),
all subject to vesting, adjustment and upon the terms and conditions as hereinafter provided, and is entitled also to exercise
the other appurtenant rights, powers and privileges hereinafter described.

 

Certain terms used in this Warrant are
defined in Article IV hereof.

 

ARTICLE
I.

 

METHOD OF EXERCISE

 

Section
1.01         Vesting; Time of Exercise.

 

(a)          This
Warrant shall vest over six months, commencing on the date hereof, in semi-monthly increments on the fifteenth and last day of
each calendar month (each a “Vesting Date”), with the first 1/12th of the total number of Warrant Shares
being vested on April 30, 2014, and thereafter 1/12th on each Vesting Date until fully vested with any unvested Warrant
Shares being vested on the last Vesting Date; provided that the vesting of the Warrant Shares shall be accelerated
and be fully vesting upon the earlier to occur of the following: (i) the Company obtaining at least $2 million upon the consummation
of a financing (or series of financings) involving the sale of equity securities, issuance of debt securities, whether convertible
into equity of the Company or not, or another financing transaction such as a sale lease back, that generates $2 million in cash
for the Company; or (ii) payments in connection with a corporate collaboration, joint venture, licensing arrangement or other partnering
arrangement of at least $2 million in either an equity investment or convertible debt, or a milestone or other fees or payments
thereunder. The Holder may exercise all or any part of Warrant but only to the extent that the underlying Warrant Shares had vested
before the Holder’s employment terminated (or vested as a result of the termination). The unvested balance of such Warrant,
if any, shall lapse when the Holder’s employment with the Company terminates. To the extent that the Holder’s employment
agreement with the Company, as may be amended, provides any additional terms which govern the vesting, acceleration and exercise
of this Warrant, such terms shall be incorporated herein by reference.

 

    	1

    	 

    

 

(b)          Subject
to the provisions of Section 1.02 and 1.03 hereof, this Warrant to the extent that it is vested as set forth in this Section 1.01
may be exercised in whole or in part at any time and from time to time prior to the Expiration Time.

 

Section
1.02         Method of Exercise.

 

		(a)	To exercise this Warrant in whole or in part, the Holder shall deliver to the Company’s principal executive office (i)
this Warrant, (ii) a written notice of such Holder’s election to exercise this Warrant in the form attached hereto as Exhibit
A and (iii) payment of an amount equal to the Exercise Price multiplied by the total number of Warrant Shares for which this Warrant
is then being exercised. Such payment may be made, at the option of the Holder, in cash, by certified or bank cashier’s check,
money order or wire transfer, or any combination thereof, or in any other manner consented to in writing by the Company.

 

		(b)	In lieu of cash exercising this Warrant in accordance with (a) above, at any time from and after a Deemed Liquidation Event
(as defined in the Company Certificate), the Holder may elect to receive shares equal to the value of this Warrant (or the portion
thereof being canceled) by surrender of this Warrant to the Company together with notice of such election, in which event the Company
shall issue to the Holder hereof a number of Shares computed using the following formula:

 

	 	Y (A-B)	 
	X=	A	 

 

Where:

 

X equals the number of Warrant Shares to be issued
to the Holder;

 

Y equals the number of Warrant Shares purchasable
under the Warrant, or, if only a portion of the Warrant is being exercised, the portion of the Warrant being exercised at the date
of such calculation;

 

    	2

    	 

    

 

A equals the Fair Market Value of one Warrant Share
(at the date of such calculation); and

 

B equals the Exercise Price (as adjusted to the date
of such calculations).

 

		(c)	The Company shall, as promptly as practicable after receipt of the items required by this Section 1.02, execute and deliver
or cause to be executed and delivered, in accordance with such notice, a certificate or certificates representing the Warrant Shares
specified in such notice. The share certificate or certificates so delivered shall be in such denominations as shall be specified
in such notice and shall be issued in the name of the Holder or, provided, in an opinion of counsel reasonably acceptable to the
Company, the following is permitted under the Act and applicable state securities law, such other name as shall be designated in
such notice. Such certificate or certificates shall be deemed to have been issued, and such Holder or Holders or any other person
so designated to be named therein shall be deemed for all purposes to have become a Holder of record of such shares as of the date
the aforementioned notice is received by the Company. If this Warrant shall have been exercised only in part, the Company shall,
at the time of delivery of the certificate or certificates, deliver to the Holder a new Warrant evidencing the right to purchase
the remaining Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical to this Warrant,
or, at the request of the Holder, appropriate notations may be made on this Warrant which shall then be returned to the Holder.
The Company shall pay all expenses, taxes and other charges payable in connection with the preparation, issuance and delivery of
share certificates and new Warrants, except that, if share certificates or new Warrants shall be registered in a name or names
other than the name of the Holder, funds sufficient to pay all transfer taxes, if any, payable as a result of such transfer shall
be paid by the Holder at the time of delivering the aforementioned notice of exercise or promptly upon receipt of a written request
of the Company for payment.

 

Section
1.03         Shares to be Fully Paid and Nonassessable. All shares of
Series B Preferred Stock issued upon exercise of the Warrant shall be validly issued, fully paid and nonassessable.

 

Section
1.04         No Fractional Shares to be Issued. The Company shall not
be required to issue fractions of Warrant Shares upon exercise of this Warrant. If any fractions of a share would, but for this
Section, be issuable upon any exercise of this Warrant, in lieu of such fractional share the Company shall pay to the Holder, in
cash, an amount equal to the same fraction of the fair market value of one share of Series B Preferred Stock.

 

Section
1.05         Share Legend. Each certificate for Warrant Shares issued
upon exercise of this Warrant, unless at the time of exercise such shares are registered under the Act, shall bear a legend substantially
as follows or similar legend as determined in good faith by the Company’s Board of Directors:

 

    	3

    	 

    

 

 

THE SECURITIES REPRESENTED BY
THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS AND
MAY NOT BE TRANSFERRED, SOLD OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT WITH RESPECT TO THE
SECURITIES EVIDENCED BY THIS CERTIFICATE, FILED AND MADE EFFECTIVE UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND SUCH APPLICABLE
STATE SECURITIES LAWS, OR UNLESS SOLD PURSUANT TO AN EXEMPTION FROM SUCH REGISTRATION REQUIREMENTS PROVIDED THAT THE COMPANY RECEIVES
AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY TO THE EFFECT THAT REGISTRATION UNDER SUCH ACT AND SUCH APPLICABLE STATE SECURITIES
LAWS IS NOT REQUIRED.

 

Any certificate issued at any time in exchange
or substitution for any certificate bearing such legend (except a new certificate issued upon completion of a public distribution
pursuant to a registration statement under the Act) shall also bear such legend unless, in the opinion of counsel reasonably acceptable
to the Company, the securities represented thereby no longer need to be subject to restrictions on resale under the Act.

 

Section
1.06         Reservation of Stock. The Company agrees during the term
the rights under this Warrant are exercisable to reserve and keep available from its authorized and unissued shares of Series B
Preferred Stock for the purpose of effecting the exercise of this Warrant such number of shares of Series B Preferred Stock (and
shares of the Company’s Common Stock for issuance upon conversion of such Warrant Shares) as shall from time to time be sufficient
to effect the exercise of the rights under this Warrant.

 

Section
1.07         Transfers. Neither this Warrant nor any rights hereunder
may be assigned, conveyed or transferred, in whole or in part, without the Company’s prior written consent, which the Company
may withhold in its sole discretion; provided, however, that this Warrant: (a) may be pledged without the prior written
consent of the Company to any lender to the Holder as part of a bona fide secured loan or credit facility (and, following a default
thereunder, this Warrant may be transferred to such lender without the Company’s consent), and (b) may be assigned, conveyed
or transferred without the prior written consent of the Company to any Affiliate of the Holder; provided, further, that
Holder surrenders this Warrant properly endorsed or accompanied by written instructions of transfer in the form attached hereto
as Exhibit B, and any such permitted transferee executes an acknowledgement that such transferee is subject to all the terms
and conditions of this Warrant and satisfies the Company as to compliance with state and federal securities law. 

 

    	4

    	 

    

 

ARTICLE
II.

 

WARRANT ADJUSTMENTS

 

Section
2.01         Merger. If at any time there shall be a merger, acquisition
or consolidation of the Company with or into another corporation, where the Company is not the surviving corporation, or a sale
of all or substantially all of the Company’s assets, then, as a part of such merger or consolidation, lawful provision shall
be made so that the Holder shall thereafter be entitled to receive upon exercise of this Warrant, during the period specified herein
and upon payment of the aggregate Exercise Price then in effect, the number of shares of stock or other securities, cash or other
property of the successor corporation resulting from such merger or consolidation, to which a holder of the stock deliverable upon
exercise of this Warrant would have been entitled in such merger or consolidation if this Warrant had been exercised immediately
before such merger or consolidation. In any such case, appropriate adjustment shall be made in the application of the provisions
of this Warrant with respect to the rights and interests of the Holder after the merger or consolidation.

 

Section
2.02         Reclassification, etc. If the securities issuable upon
exercise of this Warrant are changed into the same or a different number of securities of any other class or classes by reclassification,
capital reorganization, conversion of all outstanding shares of the relevant class or series or otherwise (other than as otherwise
provided for herein) (a “Reclassification”), then, in any such event, in lieu of the number of Warrant Shares which
the Holder would otherwise have been entitled to receive, the Holder shall have the right thereafter to exercise this Warrant for
a number of shares of such other class or classes of stock that a holder of the number of securities deliverable upon exercise
of this Warrant immediately before that change would have been entitled to receive in such Reclassification, all subject to further
adjustment as provided herein with respect to such other shares.

 

Section
2.03         Split, Subdivision or Combination of Shares. If the Company
at any time while this Warrant remains outstanding and unexpired shall split, subdivide or combine its Series B Preferred Stock,
the Exercise Price shall be proportionately decreased and the number of Warrant Shares purchasable hereunder shall be proportionately
increased in the case of a split, payment of a stock dividend (of shares of Series B Preferred Stock) or subdivision, or the Exercise
Price shall be proportionately increased and the number of shares of Warrant Shares purchasable hereunder shall be proportionately
decreased in the case of a combination.

 

Section
2.04         Notice of Adjustments; Notices. Whenever the Exercise Price
or number of Warrant Shares issuable upon exercise hereof shall be adjusted pursuant to Article II hereof, the Company shall issue
a written notice setting forth, in reasonable detail, the event requiring the adjustment, the amount of the adjustment, the method
by which such adjustment was calculated and the Exercise Price and number of Warrant Shares purchasable hereunder after giving
effect to such adjustment, and shall cause a copy of such notice to be given in accordance with Article VI hereof.

 

    	5

    	 

    

 

ARTICLE
III.

 

REPLACEMENTS OF WARRANT CERTIFICATES

 

Section
3.01         Loss, Theft or Destruction of Warrant Certificates. Upon
receipt of evidence satisfactory to the Company of the loss, theft, destruction or mutilation of any Warrant and, in the case of
any such loss, theft or destruction, upon receipt of indemnity or security from the Holder satisfactory to the Company, or, in
the case of any such mutilation, upon surrender and cancellation of the Warrant, the Company will make and deliver, lieu of such
lost, stolen, destroyed or mutilated Warrant, a new Warrant of like tenor and representing the right to purchase the same aggregate
number of Warrant Shares.

 

Section
3.02         Change of Principal Executive Office. In the event the
Company shall change the address of its principal executive office, the Company shall give the Holder notice of any such change
within a reasonable time. Any correspondence from the Company to the Holder with an address printed on Company’s letterhead
shall fulfill this requirement.

 

ARTICLE
IV.

 

DEFINITIONS

 

The following terms, as used in this Warrant,
have the following respective meanings:

 

“Act” means the Securities
Act of 1933, as amended, and any similar or successor federal statute, and the rules and regulations of the Securities and Exchange
Commission (or its successor) thereunder, all as the same shall be in effect at the time.

 

“Affiliate” means, with respect
to the Holder, any other person who, directly or indirectly, controls, is controlled by, or is under common control with such Holder,
including, without limitation, any general partner, managing member, officer or director of such Holder or any venture capital
fund now or hereafter existing that is controlled by one or more general partners or managing members of, or shares the same management
company with, such Holder.

 

“Common Stock” means the
Company’s common stock, $0.0001 per share.

 

“Company” shall have the
meaning set forth in the first paragraph of this Warrant.

 

“Company Certificate” means
the Fourth Amended and Restated Certificate of Incorporation of the Company, as amended from time to time.

 

    	6

    	 

    

 

“Eastern Time” means Eastern
Daylight Time or Eastern Standard Time, whichever is in effect on the relevant date.

 

“Expiration Time” means 5:00
p.m. Eastern Time on April 15, 2019.

 

“Fair Market Value” shall
mean the aggregate consideration payable on account of one share of Series B Preferred Stock (on an as-converted to Common Stock
basis, as applicable) as a result of a Deemed Liquidation Event (as defined in the Company Certificate) giving rise to the Holder’s
rights under Section 1.02(b).

 

“Holder” shall have the meaning
set forth in the first paragraph of this Warrant and “Holders” shall include any and all successors and assigns of
the initial Holder with respect to this Warrant.

 

“Series B Preferred Stock”
shall mean the Company’s Series B Preferred Stock, par value $0.0001 per share.

 

“Warrant” and “Warrants”
shall mean this warrant and any warrants issued upon the partial exercise of this warrant.

 

ARTICLE
V.

 

REDEMPTION AND CANCELLATION OF WARRANTS

 

Section
5.01         Redemption of Warrants. The Warrants are not redeemable
by the Company and the Company has no right to purchase or otherwise acquire the Warrants.

 

Section
5.02         Cancellation of Warrants. The Company shall cancel any
Warrant surrendered for transfer, exchange or exercise.

 

ARTICLE
VI.

 

MISCELLANEOUS

 

Section
6.01         Notices. Except with respect to notice of a change in the
Company’s principal executive office in accordance with Section 3.02 hereof, all notices, requests and other communications
provided for herein shall be in writing, and shall be deemed duly given if delivered personally or mailed by registered or certified
mail (return receipt requested) or via overnight courier to the parties at the following addresses (or at such other address for
such party as shall be specified by written notice):

 

	(a)	If to the Company:	Enumeral Technologies, Inc.	 
	 	 	1450 Broadway, 24th Floor	 
	 	 	New York, NY 10018	 
	 	 	Attn: President	 

 

    	7

    	 

    

 

	 	with a copy to:	Duane Morris LLP	 
	 	 	100 High Street, 24th Floor	 
	 	 	Boston, MA 02110	 
	 	 	Attn: Jonathan Lourie, Esq.	 
	 	 	Telephone: 857-488-4260	 
	 	 	Facsimile:  857-401-3089	 
	 	 	 	 
	(b)	If to the Holder:	Arthur H. Tinkelenberg	 
	 		395 Schlomann Drive	 
	 		Oradell, NJ 07649	 

 

Section
6.02         Waivers; Amendments. No failure or delay of the Holder
in exercising any right, power or privilege, hereunder shall operate as a waiver thereof, nor shall any single or partial exercise
thereof, or any abandonment or discontinuance of steps to enforce such a right, power or privilege, preclude any other or further
exercise thereof or the exercise of any other right, power or privilege. The rights and remedies of the Holder are cumulative and
not exclusive of any rights or remedies which it would otherwise have. The provisions of this Warrant may be amended, modified
or waived if, but only if, such amendment, modification or waiver is in writing and is signed by the Holder.

 

Section
6.03         Governing Law. This Warrant shall be construed in accordance
with and governed by the laws of the State of Delaware, without regard to the conflict of laws rules thereof to the extent that
the application of the law of another jurisdiction would be required thereby.

 

Section
6.04         Survival of Agreements; Representations and Warranties, etc.
All warranties, representations and covenants made by the Company herein or in any certificate or other instrument delivered by
or on behalf of it in connection herewith shall be considered to have been relied upon by the Holder and shall survive the issuance
and delivery of the Warrants and shall continue in full force and effect so long as this Warrant is outstanding. All statements
in any such certificate or other instrument shall constitute representations and warranties hereunder.

 

Section
6.05         Covenants to Bind Successors and Assigns. All the covenants,
stipulations, promises and agreements in this Warrant contained by or on behalf of the Company shall bind its successors and assigns,
whether or not so expressed.

 

Section
6.06         Severability. In case any one or more of the provisions
contained in this Warrant shall be invalid, illegal or unenforceable in any jurisdiction, the validity, legality and enforceability
of the remaining provisions contained herein and therein shall not in any way be affected or impaired in such jurisdiction and
shall not invalidate or render illegal or unenforceable such provision in any other jurisdiction.

 

    	8

    	 

    

 

Section
6.07         Headings. The headings used herein are for convenience
of reference only and shall not be deemed to be a part of this Warrant.

 

Section
6.08         No Rights as Stockholder. This Warrant shall not entitle
the Holder to any rights as a stockholder of the Company.

 

Section
6.09         No Impairment. The Company shall not, by amendment of the
Company Certificate or through a reorganization, transfer of assets, consolidation, merger, dissolution, issue, or sale of securities
or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed
under this Warrant by the Company, but shall at all times in good faith assist in carrying out of all the provisions of this Warrant
and in taking all such action as may be necessary or appropriate to protect the Holder’s rights under this Warrant against
impairment.

 

Section 6.10         Pronouns.
The pronouns “it” and “its” herein shall be deemed to mean “he” and “his” or “she”
and “hers,” as the context requires.

 

[The remainder of this
page intentionally left blank – signature page follows] 

 

    	9

    	 

    

IN WITNESS WHEREOF, Enumeral Biomedical Corp.
has caused this Warrant to be executed in its corporate name by one of its officers thereunto duly authorized as of the day and
year first above written.

 

	 	ENUMERAL BIOMEDICAL CORP.
	 	 	 
	 	By:	/s/ John J. Rydzewski
	 	 	Name:	John J. Rydzewski
	 	 	Title:	Executive Chairman

 

    	10

    	 

    

 

EXHIBIT
A

 

FORM
OF NOTICE OF EXERCISE

 

[To be signed only upon exercise of the
Warrant]

 

		TO:	Enumeral Biomedical Corp.

 

1.          The undersigned
hereby elects to purchase __________ shares of _____________ pursuant to the terms of the attached Warrant.

 

2.          Method of
Exercise (Please initial the applicable blank):

 

		___	The undersigned elects to exercise the attached Warrant by means of a cash payment, and tenders
herewith payment in full for the purchase price of the shares being purchased, together with all applicable transfer taxes, if
any.

 

		___	The undersigned elects to exercise the attached Warrant by means of the net exercise provisions
of Section 1.02(b) of the Warrant.

 

3.          Please
issue a certificate or certificates representing said Shares in the name of the undersigned or in such other name as is specified
below:

 

	 	 	 
	 	(Name)	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	(Address)	 

 

4.          The
undersigned hereby represents and warrants that the aforesaid Shares are being acquired for the account of the undersigned for
investment and not with a view to, or for resale, in connection with the distribution thereof, and that the undersigned has no
present intention of distributing or reselling such shares.

 

	 	 	 	 
	 	 	(Signature)	 
	 	 	 	 
	 	 	 	 
	 	 	(Name)	 
	 	 	 	 
	 	 	 	 
	(Date)	 	(Title)	 

 

    	 

    	 

    

 

EXHIBIT B

 

FORM OF TRANSFER

(To be signed only upon transfer of Warrant)

 

FOR VALUE RECEIVED,
the undersigned hereby sells, assigns and transfers unto _______________________________________________ the right represented
by the attached Warrant to purchase ____________ shares of Series B Preferred Stock of Enumeral Biomedical Corp. to which the attached
Warrant relates, and appoints ______________ Attorney to transfer such right on the books of __________, with full power of substitution
in the premises.

 

	Dated: 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	(Signature must conform in all respects to name of Holder as specified on the face of the Warrant)
	 	 	 	 	 	 
	 	 	 	 	Address:	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	Signed in the presence of:Enumeral Biomedical Holdings, Inc.

2014 Equity Incentive Plan

 

Incentive Stock Option Agreement

 

Dear John J. Rydzewski,

 

On July 31, 2014, the Compensation Committee
approved a grant of an Incentive Stock Option (the "Option") to you to purchase Common Stock of Enumeral Biomedical Holdings,
Inc. (the "Company") pursuant to the Enumeral Biomedical Holdings, Inc. 2014 Equity Incentive Plan (the "Plan").
The Option shall constitute and be treated at all times by you and the Company as an “incentive stock option,” as defined
under Section 422(b) of the Internal Revenue Code of 1986, as amended.

 

You are granted an Option to purchase 300,000
shares of Common Stock of the Company at the price of $1.00 per share which represents the Fair Market Value of the Common Stock
on the date of grant. The date of grant of this Option is July 31, 2014.

 

1.          Vesting.
This Option may be exercised only to the extent it is vested. Subject to you remaining in the employ of the Company on the applicable
vesting dates below, this Option shall vest as follows:

 

		(a)	100,000 shares shall vest monthly over 4 years in 48 equal monthly installments, beginning on July 31, 2014 ("New Option
A"); and

 

		(b)	200,000 shares ("New Option B") shall vest upon the earlier
of (1) upon the price of the Company’s common stock being above $3, $4, $5, $6, $7, $8, $9 and $10 per share (each a “Price
Based Vesting Milestone”) on a volume-weighted daily basis (adjusted for any stock-splits, recapitalizations or dividends)
for at least 60 trading days following the earlier to occur of the Transition Event or the filing of the first registration statement
with the Securities and Exchange Commission for registering common stock of the Company, or for at least 30 trading days following
the effective date of the first registration statement (“Measuring Period”) with such vesting to occur evenly across
all stock prices provided that if a higher Price Based Vesting Milestone is maintained for the Measuring Period, then the lower
Priced Based Vesting Milestones shall also be deemed to have been achieved; or (2) entering into one or more collaborations or
joint ventures with third party biotechnology, pharmaceutical or other companies in the life sciences or healthcare industry sector
under which the Company, would receive gross proceeds of at least $20 million, with twenty five percent (25%) of the shares covered
by New Option B vesting upon each receipt by the Company, of $5 million increments of gross proceeds to the Company (“Collaboration
Proceeds”). The above vesting is additive, not exclusionary, and is based on the original amount of the grant, of New Option
B without reduction for earlier vesting, meaning that, for example, if the Company, achieves the Price Based Vesting Milestone
for the Measuring Period and then the Company, receives $5 million in Collaboration Proceeds, the Executive would be entitled to
vest on 25,000 shares or 12.5% of the original grant amount of New Option B plus 50,000 shares or 25% of the original grant amount
of New Option B.

 

    	 

    	 

    

 

2.          Duration
of Option. Except as otherwise provided herein, this option may be exercised for three (3) months after you terminate employment
with the Company, provided, however in the event your termination of employment is due to your death or disability, the Option
may be exercised for one year following such event. In no case, however, may the Option be exercised after July 31, 2024.

 

3.          Exercise
of Option.

 

(a)          Right
to Exercise. This Option is exercisable during its term in accordance with the Vesting Schedule set out in Section 1.

 

(b)          Method
of Exercise. This Option is exercisable by delivery of an exercise notice, in the form attached as Exhibit A (the "Exercise
Notice"), which shall state the election to exercise the Option, the number of shares of Common Stock in respect of which
the Option is being exercised (the "Exercised Shares"), and such other representations and agreements as may be required
by the Company pursuant to the provisions of the Plan. The Exercise Notice shall be completed by you and delivered to the Corporate
Secretary. The Exercise Notice shall be accompanied by payment of the aggregate exercise price as to all Exercised Shares. This
Option shall be deemed to be exercised upon receipt by the Company of such fully executed Exercise Notice accompanied by such aggregate
exercise price.

 

No shares of Common Stock shall be issued pursuant
to the exercise of this Option unless such issuance and exercise comply with applicable laws. Assuming such compliance, for income
tax purposes the exercised Shares shall be considered transferred to you on the date the Option is exercised with respect to such
Exercised Shares.

 

4.          Method
of Payment. Payment of the aggregate Exercise Price shall be by any of the following, or a combination thereof, at your election:

 

(a)          cash;

 

(b)          check;

 

(c)          consideration
received by the Company under a cashless exercise program implemented by the Company in connection with the Plan; or

 

(d)          surrender
of other shares of Common Stock which (i) in the case of shares of Common Stock acquired upon exercise of an option, have been
owned by you for more than six (6) months on the date of surrender, AND (ii) have a fair market value on the date of surrender
equal to the aggregate Exercise Price of the Exercised Shares.

 

    	2

    	 

    

 

5.          Non-Assignability
of Option. This Option may not be transferred in any manner otherwise than by will or by the laws of descent or distribution
and may be exercised during your lifetime only by you except in the case of your disability, this Option may be exercised by your
representative. The terms of the Plan and this Agreement shall be binding upon your executors, administrators, heirs, successors
and assigns.

 

The Plan is incorporated herein by reference.
The Plan and this Agreement constitute the entire agreement of the parties with respect to the subject matter hereof and supersede
in their entirety all prior undertakings and agreements of the Company and you with respect to the subject matter hereof, and may
not be modified adversely to your interest except by means of a writing signed by the Company and you. This Agreement is governed
by the laws of the State of Delaware.

 

[Signature page follows]

 

    	3

    	 

    

 

By your signature and the signature of the Company's representative
below, you and the Company agree that the Option is granted under and governed by the terms and conditions of the Plan and this
Agreement. You have reviewed the Plan and this Agreement in their entirety, have had an opportunity to obtain the advice of counsel
prior to executing this Agreement and fully understand all provisions of the Plan and this Agreement. You hereby agree to accept
as binding, conclusive and final all decisions or interpretations of the Committee upon any questions relating to the Plan and
Agreement. You further agree to notify the Company upon any change in your residence address indicated below.

 

	PARTICIPANT	 	ENUMERAL BIOMEDICAL
	 	 	HOLDINGS, INC.
	 	 	 
	/s/ John J. Rydzewski	 	/s/ Arthur H. Tinkelenberg
	Signature	 	By: Arthur H. Tinkelenberg
	 	 	 
	John J. Rydzewski	 	Chief Executive Officer
	Print Name	 	Title
	 	 	 
	One West 72nd St., Apt 30	 	 
	New York, NY 10023	 	 
	 	 	 
	 	 	 
	Residence Address	 	 

 

    	4

    	 

    

 

Exhibit A

EXERCISE NOTICE

 

Enumeral Biomedical Holdings, Inc.

One Kendall Square

Building 400, 4th Floor

Cambridge, MA 02139

 

————————

(date)

 

Re: Incentive Stock Option

 

Notice is hereby given pursuant to Section
3 of my Agreement that I elect to purchase the number of shares set forth below at the exercise price set forth in my Agreement:

 

	Stock Option dated:	 	 
	 	 	 
	Number of shares being purchased:	 	 
	 	 	 
	Option Exercise Price Per Share	 	 
	 	 	 
	Aggregate Option Exercise Price	 	 

 

A check in the amount of the aggregate price
of the shares being purchased is attached.

 

I understand that the shares of Common Stock
that I receive upon exercise of my Option may not be freely tradable.

 

Further, I understand that, as a result of
this exercise of rights, I will recognize income in an amount equal to the amount by which the fair market value of the shares
of Common Stock exceeds the exercise price. I agree to report such income in accordance with then applicable law and to cooperate
with the Company in establishing the withholding and corresponding deduction to the Company for its income tax purposes.

 

I agree to provide to the Company such additional
documents or information as may be required pursuant to the Company’s 2014 Equity Incentive Plan.

 

	 	 
	 	(Signature)
	 	 
	 	 
	 	 
	 	 
	 	(Name of Optionee)

 

    	5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00234-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00234-of-00352.parquet"}]]